WallStreetZenWallStreetZen

NASDAQ: VRAX
Virax Biolabs Group Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VRAX

Based on 1 analyst offering 12 month price targets for Virax Biolabs Group Ltd

Min Forecast
$3.00+228.59%
Avg Forecast
$3.00+228.59%
Max Forecast
$3.00+228.59%

Should I buy or sell VRAX stock?

Based on 1 analyst offering ratings for Virax Biolabs Group Ltd.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although VRAX's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates VRAX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their VRAX stock forecasts and price targets.

VRAX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-31

1 of 1

Forecast return on equity

Is VRAX forecast to generate an efficient return?

Company
-50.73%
Industry
1,575.97%
Market
76.96%
VRAX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VRAX forecast to generate an efficient return on assets?

Company
-46.44%
Industry
1,136.33%
VRAX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VRAX earnings per share forecast

What is VRAX's earnings per share in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.01

VRAX revenue forecast

What is VRAX's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$40.0M+47,029.8%
VRAX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VRAX revenue growth forecast

How is VRAX forecast to perform vs Biotechnology companies and vs the US market?

Company
47,029.8%
Industry
3,251.13%
Market
59.56%
VRAX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VRAX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VRAX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VRAX$0.91$3.00+228.59%Buy
SONN$1.30$20.00+1,438.46%Strong Buy
OGEN$0.18N/AN/A
KTTA$1.43N/AN/A
MBIO$1.23N/AN/A
View Top Biotech Stocks

Virax Biolabs Group Stock Forecast FAQ

Is Virax Biolabs Group Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: VRAX) stock is to Buy VRAX stock.

Out of 1 analyst, 0 (0%) are recommending VRAX as a Strong Buy, 1 (100%) are recommending VRAX as a Buy, 0 (0%) are recommending VRAX as a Hold, 0 (0%) are recommending VRAX as a Sell, and 0 (0%) are recommending VRAX as a Strong Sell.

If you're new to stock investing, here's how to buy Virax Biolabs Group stock.

What is VRAX's earnings growth forecast for 2026-2026?

(NASDAQ: VRAX) Virax Biolabs Group's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 46.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 71.14%.

Virax Biolabs Group's earnings in 2025 is -$6,580,312.

In 2026, VRAX is forecast to generate -$4,385,376 in earnings, with the lowest earnings forecast at -$4,385,376 and the highest earnings forecast at -$4,385,376.

What is VRAX's revenue growth forecast for 2026-2026?

(NASDAQ: VRAX) Virax Biolabs Group's forecast annual revenue growth rate of 47,029.8% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 3,251.13%, and it is also forecast to beat the US market's average forecast revenue growth rate of 59.56%.

Virax Biolabs Group's revenue in 2025 is $84,872.

In 2026, VRAX is forecast to generate $173,678,240 in revenue, with the lowest revenue forecast at $173,678,240 and the highest revenue forecast at $173,678,240.

What is VRAX's forecast return on assets (ROA) for 2026-2026?

(NASDAQ: VRAX) forecast ROA is -46.44%, which is lower than the forecast US Biotechnology industry average of 1,136.33%.

What is VRAX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year VRAX price target, the average VRAX price target is $3.00, with the highest VRAX stock price forecast at $3.00 and the lowest VRAX stock price forecast at $3.00.

The Wall Street analyst predicted that Virax Biolabs Group's share price could reach $3.00 by Mar 31, 2026. The average Virax Biolabs Group stock price prediction forecasts a potential upside of 228.59% from the current VRAX share price of $0.91.

What is VRAX's Earnings Per Share (EPS) forecast for 2026-2026?

(NASDAQ: VRAX) Virax Biolabs Group's current Earnings Per Share (EPS) is -$2.61. In 2026, VRAX's EPS is forecast to hit -$1.01 (min: -$1.01, max: -$1.01).

What is VRAX's forecast return on equity (ROE) for 2026-2026?

(NASDAQ: VRAX) forecast ROE is -50.73%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.